194 related articles for article (PubMed ID: 27192950)
21. IMMUNOTHERAPY. Could microbial therapy boost cancer immunotherapy?
Snyder A; Pamer E; Wolchok J
Science; 2015 Nov; 350(6264):1031-2. PubMed ID: 26612936
[No Abstract] [Full Text] [Related]
22. Exacerbation of Autoimmune Thyroiditis by CTLA-4 Blockade: A Role for IFNγ-Induced Indoleamine 2, 3-Dioxygenase.
Sharma R; Di Dalmazi G; Caturegli P
Thyroid; 2016 Aug; 26(8):1117-24. PubMed ID: 27296629
[TBL] [Abstract][Full Text] [Related]
23. Immunological basis of melanoma-associated vitiligo-like depigmentation.
González R; Torres-López E
Actas Dermosifiliogr; 2014 Mar; 105(2):122-7. PubMed ID: 23146137
[TBL] [Abstract][Full Text] [Related]
24. Anti-tyrosinase-related protein-2 immune response in vitiligo patients and melanoma patients receiving active-specific immunotherapy.
Okamoto T; Irie RF; Fujii S; Huang SK; Nizze AJ; Morton DL; Hoon DS
J Invest Dermatol; 1998 Dec; 111(6):1034-9. PubMed ID: 9856813
[TBL] [Abstract][Full Text] [Related]
25. [The "immune checkpoints", how does it work].
Granier C; Soumelis V; Mandavit M; Gibault L; Belazzoug R; de Guillebon E; Badoual C; Tartour E; Roussel H
Ann Pathol; 2017 Feb; 37(1):18-28. PubMed ID: 28160999
[TBL] [Abstract][Full Text] [Related]
26. Blunted epidermal L-tryptophan metabolism in vitiligo affects immune response and ROS scavenging by Fenton chemistry, part 2: Epidermal H2O2/ONOO(-)-mediated stress in vitiligo hampers indoleamine 2,3-dioxygenase and aryl hydrocarbon receptor-mediated immune response signaling.
Schallreuter KU; Salem MA; Gibbons NC; Maitland DJ; Marsch E; Elwary SM; Healey AR
FASEB J; 2012 Jun; 26(6):2471-85. PubMed ID: 22415306
[TBL] [Abstract][Full Text] [Related]
27. Initiation and regulation of CD8+T cells recognizing melanocytic antigens in the epidermis: implications for the pathophysiology of vitiligo.
Steitz J; Wenzel J; Gaffal E; Tüting T
Eur J Cell Biol; 2004 Dec; 83(11-12):797-803. PubMed ID: 15679123
[TBL] [Abstract][Full Text] [Related]
28. B7 costimulation and intracellular indoleamine-2,3-dioxygenase expression in peripheral blood of healthy pregnant and pre-eclamptic women.
Toldi G; Vásárhelyi B; Biró E; Fügedi G; Rigó J; Molvarec A
Am J Reprod Immunol; 2013 Mar; 69(3):264-71. PubMed ID: 23289444
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies.
Philips GK; Atkins M
Int Immunol; 2015 Jan; 27(1):39-46. PubMed ID: 25323844
[TBL] [Abstract][Full Text] [Related]
30. Melanoma-Derived Wnt5a Promotes Local Dendritic-Cell Expression of IDO and Immunotolerance: Opportunities for Pharmacologic Enhancement of Immunotherapy.
Holtzhausen A; Zhao F; Evans KS; Tsutsui M; Orabona C; Tyler DS; Hanks BA
Cancer Immunol Res; 2015 Sep; 3(9):1082-95. PubMed ID: 26041736
[TBL] [Abstract][Full Text] [Related]
31. Vitiligo: Focus on Clinical Aspects, Immunopathogenesis, and Therapy.
Boniface K; Seneschal J; Picardo M; Taïeb A
Clin Rev Allergy Immunol; 2018 Feb; 54(1):52-67. PubMed ID: 28685247
[TBL] [Abstract][Full Text] [Related]
32. Next generation of immunotherapy for melanoma.
Kirkwood JM; Tarhini AA; Panelli MC; Moschos SJ; Zarour HM; Butterfield LH; Gogas HJ
J Clin Oncol; 2008 Jul; 26(20):3445-55. PubMed ID: 18612161
[TBL] [Abstract][Full Text] [Related]
33. Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis.
Teulings HE; Limpens J; Jansen SN; Zwinderman AH; Reitsma JB; Spuls PI; Luiten RM
J Clin Oncol; 2015 Mar; 33(7):773-81. PubMed ID: 25605840
[TBL] [Abstract][Full Text] [Related]
34. FoxP3, CTLA-4, and IDO in Canine Melanocytic Tumors.
Porcellato I; Brachelente C; Cappelli K; Menchetti L; Silvestri S; Sforna M; Mecocci S; Iussich S; Leonardi L; Mechelli L
Vet Pathol; 2021 Jan; 58(1):42-52. PubMed ID: 33021155
[TBL] [Abstract][Full Text] [Related]
35. Skin-resident memory T cells as a potential new therapeutic target in vitiligo and melanoma.
Willemsen M; Linkutė R; Luiten RM; Matos TR
Pigment Cell Melanoma Res; 2019 Sep; 32(5):612-622. PubMed ID: 31230406
[TBL] [Abstract][Full Text] [Related]
36. Immune-related adverse events with immune checkpoint blockade: a comprehensive review.
Michot JM; Bigenwald C; Champiat S; Collins M; Carbonnel F; Postel-Vinay S; Berdelou A; Varga A; Bahleda R; Hollebecque A; Massard C; Fuerea A; Ribrag V; Gazzah A; Armand JP; Amellal N; Angevin E; Noel N; Boutros C; Mateus C; Robert C; Soria JC; Marabelle A; Lambotte O
Eur J Cancer; 2016 Feb; 54():139-148. PubMed ID: 26765102
[TBL] [Abstract][Full Text] [Related]
37. HSP70i
Henning SW; Fernandez MF; Mahon JP; Duff R; Azarafrooz F; Guevara-Patiño JA; Rademaker AW; Salzman AL; Le Poole IC
J Invest Dermatol; 2018 Dec; 138(12):2531-2539. PubMed ID: 30031029
[TBL] [Abstract][Full Text] [Related]
38. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy.
Rosenberg SA; White DE
J Immunother Emphasis Tumor Immunol; 1996 Jan; 19(1):81-4. PubMed ID: 8859727
[TBL] [Abstract][Full Text] [Related]
39. Immune checkpoint inhibition in ovarian cancer.
Hamanishi J; Mandai M; Konishi I
Int Immunol; 2016 Jul; 28(7):339-48. PubMed ID: 27055470
[TBL] [Abstract][Full Text] [Related]
40. PD-L1 and immune escape: insights from melanoma and other lineage-unrelated malignancies.
Frydenlund N; Mahalingam M
Hum Pathol; 2017 Aug; 66():13-33. PubMed ID: 28694003
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
